Use of tissue adhesives in the management of paediatric lacerations

A Mattick

The ideal method of wound closure in children who present to the accident and emergency department with lacerations, is painless, rapid, easy to perform, safe, and results in minimal scarring. Tissue adhesives have recently been used as a “no needle” alternative to conventional suturing. This review reports on the development of tissue adhesives and analyses how close they are to this ideal method of wound closure.

Lacerations requiring formal wound closure account for a significant number of all childhood injuries presenting to the accident and emergency department. Figures vary from 30%–40% of all paediatric injuries and 3%–4.4% of all paediatric attendances. Their management represents a unique challenge because of the developmental and behavioural characteristics of this group of patients. Indeed, to a child, the thought of needles, sutures, or staples may be worse than the actual injury itself. Therefore, the ideal method of wound closure in children should be not only painless but also rapid, easy to perform, safe, with few complications, and result in minimal scarring. Clearly, closure with conventional suturing techniques fail to accomplish all these goals in their entirety. The recent advances made in the field of tissue adhesives have led to its development as a “no needle” method of wound closure that may allay the fears of the frightened child during laceration repair, and provide a good cosmetic result without the need for sedation or anaesthetics.

OBJECTIVE
This review reports on the development of these tissue adhesives and analyses how close to the ideal method this technique is in repairing children’s lacerations.

METHODOLOGY
A literature search was undertaken using the Medline 1966–2001 and Cochrane databases. The key words used were: tissue adhesives, cyanoacrylates, Dermabond, Histacryl Blue, glue, wound and injuries, laceration, child, and paediatric. Cross referencing was then undertaken manually.

DEVELOPMENT OF CYANOACRYLATE TISSUE ADHESIVES
Cyanoacrylate adhesives were first synthesised in 1949 by Ardis. As a group they have a common chemical structure but subtle variations in the alkyl group can change the properties of each individual tissue adhesive (fig 1). Cyanoacrylates are liquid monomers that can polymerise to form a rapid and strong adhesive. This process occurs when they come into contact with anions, such as those found in skin moisture or wound exudate. Thus, when applied to the edges of a wound a strong bond will develop, allowing wound closure.

The early derivatives methyl-2-cyanoacrylate (Eastman 910 Monomer) and ethyl-2-cyanoacrylate (Krazy glue) produced good bonding but resulted in histotoxicity giving rise to wound inflammation. Their clinical use was therefore hindered. The causes of this histotoxicity were short chain alkyl derivatives, which degraded rapidly into cyanoacetate and formaldehyde. These breakdown products could not be excreted at a sufficient rate to prevent their accumulation locally in the tissues, leading to levels that resulted in inflammation. It was not until the development of longer chain alkyl derivatives, which degraded more slowly, that tissue adhesives became useful clinically. Their slow degradation enabled excretion of the toxic breakdown products preventing a build up. These newer derivatives are N-butyl-2-cyanoacrylate (Histacryl Blue), the first tissue adhesive to be successfully used clinically, and the most recent formulation, octyl-2-cyanoacrylate (Dermabond), which has reputed advantages over the Histoacryl Blue. The following review thus concentrates on these two tissue adhesives.

APPLICATION OF ADHESIVES FOR WOUND CLOSURE
After routine wound management the edges of the wounds are held together with either forceps or the operator’s fingers before the adhesive is applied. Histoacryl Blue is applied as beads intermittently along the edge of the laceration whereas Dermabond is painted on in layers. Whichever adhesive is used, the edges of the wound are held together for up to a minute to enable sufficient polymerisation and bond formation to achieve closure. Maximum strength is
usually achieved within two minutes. It is important that the adhesives are placed topically onto the wound edges and not allowed to enter the wound itself, as this will impair healing. A sterile, waterproof seal is formed, allowing the patient to briefly shower but not to soak. No additional dressing need be applied, unless it is thought that the child may pick at the wound, and the adhesive is allowed to slough off naturally in one to two weeks. 

Specific hazards include gluing oneself to the child and getting glue in the child’s eye. The former embarrassing situation is remedied by applying petroleum jelly or acetone to loosen the bond and then peel, not pull, the surfaces apart. The second hazard is usually avoided by protection of the child’s eyes with gauze when closing facial wounds. If this fails and adhesive inadvertently enters the eye, then ophthalmic ointment should be applied, and the glue patched. The glue will slough off in one to two days.

**CLINICAL TRIALS INVOLVING THE TISSUE ADHESIVES**

**N-butyl-2-cyanoacrylate (Histoacryl Blue)**

Since 1988 numerous uncontrolled reports in the literature have advocated the use of Histoacryl Blue in the repair of paediatric lacerations. They highlight the virtues of its ease of use, patient acceptability, low complication rates, and excellent cosmetic outcome. The number of children involved in these observational studies varies from 50–2600. Similar studies have reported the same outcomes in repairing adult lacerations, and in the closure of elective surgical incisions. All of these studies are, however, limited in that they lack control groups and blinded, validated outcome measures. It was not until 1993 that the first of three randomised controlled trials compared Histoacryl Blue with suturing in the closure of paediatric lacerations. Quinn et al randomised 81 children with facial lacerations less than 4 cm in length for repair using either Histoacryl Blue or 5/0 non-absorbable sutures. Three month post-repair photographs were shown to two plastic surgeons blinded as to the method of closure. They independently rated the scars using two validated cosmesis scales. The first is a visual analogue scale on which the surgeon marks a 100 mm line, annotated with “worse scar” and “best scar” at either ends, where he feels the scar best fits. The second is a categorical scale where the surgeon is provided with criteria to rate the scar into three categories; unacceptable, adequate, or excellent. Using these scoring systems the study showed no difference in the cosmetic outcome in the two groups. The study also demonstrated that the tissue adhesive technique was a faster procedure and perceived to be less painful. Both groups had low rates of complications.

In the second of these types of trials Bruns et al showed similar findings after randomising 61 children with “low-tension” facial and scalp lacerations. The cosmetic appearance in both groups was judged comparable at two months and remained so at one year. The authors also commented that parents whose offspring had been treated with tissue adhesives were more likely to recommend this over suturing to other parents.

In the third trial Barnett et al confirmed the findings of the previous two studies. In this, the largest of the three trials, 163 children were randomised for closure with tissue adhesive or sutures. For the first time wounds other than those on the face or scalp were included.

When focusing on these three studies it must be emphasised that the great majority of lacerations were low tension in nature and involved the face or scalp. All were less than 5 cm in length with the highest mean length of the three studies, 1.6 cm. In clinical practice, however, this is a realistic pattern.

Therefore, there is now clinical evidence that this tissue adhesive has advantages over sutures. It is a faster wound closure technique and seems to be less painful as judged by children and their parents. This is achieved with a comparable cosmetic outcome and an equally low complication rate.

**Octyl-2-cyanoacrylate (Dermabond)**

The most recent cyanoacrylate product is an octyl based derivative and is the first to gain FDA approval. This longer chain formulated product is a combination of monomers and a plasticiser that results in an adhesive with a three dimensional breaking strength four times that of butyl derivatives, (Histoacryl Blue). The increased strength combined with the greater degree of flexibility from the plasticisers has led to the possibility of enhanced performance over the butyl derivatives. To prove this it would have to close longer wounds, in areas other than just low tension, while maintaining excellent scarring with a low complication rate.

The first randomised controlled trial comparing Dermabond to sutures was by Quinn et al in 1997. They enrolled 136 adults with low tension lacerations of the face, torso, and extremities. The results showed Dermabond to be faster, less painful, and with similar scar outcome to sutures. Singer et al showed comparable findings in a similar trial, which included both adults and children. The average length of the lacerations in both of these trials was only just over 2 cm and if the surgeon subjectively felt that subcuticular sutures were justified to reduce wound tension, then these were used. Thus, it may be argued that the improved physical properties of this new tissue adhesive had not been tested in these studies.

They were, however, tested to some degree by Mar et al when Dermabond was compared with subcuticular sutures in the closure of 50 wounds. The wounds averaged 8 cm in length and comparable scarring was achieved. These wounds were all clean, incised wounds that had received additional subcutaneous suturing to augment wound strength.

To date, only two studies compare Dermabond with sutures in a purely paediatric population. The first involved 83 children whose lacerations were mainly facial (that is, low tension) with an average length less than 1.2 cm. Some of the wounds had subcutaneous suturing and the two methods of closure showed comparable cosmetic results. In the second study, Sexena and Willital reported on 64 children with extremity lacerations in high tension areas, for example, knee, elbow, etc. The mean length of wound was 2.4 cm. This seems to be the only study to actively seek out and test a tissue adhesive in high tension areas. They confirmed that there was no difference in scar formation or complications such as wound dehiscence between the Dermabond and suture groups. The wounds were, however, all splinted for one week to minimise tension at the wound edges. Therefore, once again, the enhanced physical properties of this new tissue adhesive seem to have been only partially tested.

Throughout these studies Dermabond seems to show all the advantages of Histoacryl Blue when compared with conventional suturing. Therefore it is quick, well tolerated, with low rates of complications, and a comparable cosmetic outcome.

**Comparison of Dermabond with Histoacryl Blue**

Dermabond has superior physical qualities to Histoacryl Blue. The two tissue adhesives, however, have only been compared with one another in one clinical trial. Osmond et al compared the two products on the facial lacerations of 94 children. All lacerations were less than 4 cm long (mean of 1.3 cm). No difference was found between the groups when comparing cosmetic outcome, time to perform the procedure, ease of use of the products, child discomfort, or complications.

**Comparison of Dermabond with Steristrips**

Adhesive strips such as Steristrips represent the other “no needle” alternative to sutures. They are an acceptable method...
of closure of lacerations that are small and under low tension. The main disadvantages are that they come away from the skin if they become wet, and that they cannot reliably be used over joints. They also cannot be applied to hairy skin.

In a unique randomised controlled trial, Steristrips were compared with Dermabond in the closure of 44 children’s lacerations. The wounds were all short, of low tension, and involved non-hairy skin. No difference was found in cosmetic outcome or complication rates.

FURTHER FACTORS INVOLVING TISSUE ADHESIVES

Advantages

Financial

In a cost comparison of Histoacryl Blue and non-absorbable sutures in the closure of facial lacerations, the tissue adhesive was the most cost efficient. The calculated saving per child at that time was $C49.60. This was mainly attributable to the follow up costs entailed in suture removal. These figures are based on the treatment of 10 children from each vial of tissue adhesive (despite the fact that it is licensed for single use only). This was achieved by attaching a sterile 25 gauge needle to the hub of the applicator for each application, an approach that has been advocated by many other authors. Even so, a saving would still have been achieved even if only one application was obtained from each vial.

Antimicrobial

In animal studies, contaminated wounds closed with Histoacryl Blue were found to have bacterial growth rates significantly less than those closed with sutures. Laboratory tests confirm both tissue adhesives to have antimicrobial effects.

Langer’s lines

In one study closure with sutures resulted in a cosmetically worse scar in lacerations that deviated by more than 20° from Langer’s lines. In contrast, closure with the tissue adhesive was unaffected by the wound’s orientation with Langer’s lines.

Miscellaneous

A wound toilet removal is required with this technique formal follow up is unnecessary. This assumes the parent or guardian is told to return at signs of infection or wound dehiscence. Finally, when used as licensed, no needles are involved and there is no risk of needlestick injury. The latter does not apply if multiple use from the one vial of Histoacryl Blue is adopted.

Disadvantages

Wound strength

In one animal study the wound strength after immediate closure of a laceration with Histoacryl Blue was 10%–15% that of a similar wound closed with suturing. A further study confirmed this relative weakness at day 4° but by day 7 it has been shown that this difference disappears. One further technical problem is that after polymerising the tissue adhesive becomes brittle and may be subject to fracturing if used on skin creases, long lacerations, or areas of movement. The three major randomised controlled trials using Histoacryl Blue, however, showed no significant difference in wound dehiscence between the methods of closure. Therefore, the clinical relevance of this relative early weakness and inflexibility would seem uncertain until it is noted that these major trials were all in short, low tension wounds.

Wound reactions

When applied correctly histotoxicity is negligible. However, incorrect placement of the tissue adhesive into the wound itself results in some minor histotoxicity, impaired healing, and can result in an unacceptable scar. The adhesive can act as a barrier to epithelisation and result in a wider scar. Furthermore, during polymerisation the reaction produces a small amount of heat that occasionally produces discomfort.

Potential carcinogenicity

Data from one study reported that isobutyl-2-cyanoacrylate implanted into rat peritoneum induced sarcomas. In this trial, however, the rats had a predisposition for sarcoma, the study was uncontrolled, and the amounts used were 100 times greater than those used in humans. Further studies have failed to show any evidence of carcinogenicity. Despite this, it is thought to have been the stumbling block for failure to achieve FDA approval in the USA and so preventing its use there.

Conclusion

The cyanoacrylate tissue adhesives Histoacryl Blue and Dermabond are excellent “no needle” alternatives for the closure of selected paediatric lacerations (table 1). The method is faster and less painful than suturing, while producing an equivalent cosmetic outcome with an equally low complication rate. Suitable wound types are those that are short, clean, and under low tension. Dermabond has the physical properties to potentially improve on the size and type of laceration that can be closed, but clinical trials to date do not appear to test this claim fully.

Despite the encouraging advantages of the tissue adhesives it is important to remember that wound closure is only part of the wound management in these children. Many wounds require irrigation, debridement, and deep sutures, which may require time, conscious sedation or anaesthesia. Although tissue adhesives are rapid and relatively painless, their use in inappropriate situations will lead to poor technical and cosmetic results.

ACKNOWLEDGEMENT

I thank Dr C Robertson and Dr T Beattie for their comments and suggestions in the preparation of this review.

Funding: none.

Conflicts of interest: none.
REFERENCES

7 Coover HN. JAMA 1997; 277: 1559–60.